HC Wainwright&Co.:下调Rallybio(RLYB.US)评级,由买入调整至中性评级。Rallybio(RLYB.US)公司简介:Rallybio Corp是一家临床阶段的生物技术公司,致力于为患有严重和罕见疾病的患者寻找并加速生命转化疗法的开发。其项目旨在预防胎儿和新生儿同种免疫性血小板减少症,这是一种可能危及生命的罕见疾病,可能导致胎儿和新生儿不受控制的出血。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.